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Abstract
Purpose of Review Although an independent brain renin-angiotensin system is often assumed to exist, evidence for this concept
is weak. Most importantly, renin is lacking in the brain, and both brain angiotensinogen and angiotensin (Ang) II levels are
exceptionally low. In fact, brain Ang II levels may well represent uptake of circulating Ang II via Ang II type 1 (AT1) receptors.
Recent Findings Nevertheless, novel drugs are now aimed at the brain RAS, i.e., aminopeptidase A inhibitors should block Ang
III formation from Ang II, and hence diminish AT1 receptor stimulation by Ang III, while AT2 and Mas receptor agonists are
reported to induce neuroprotection after stroke. The endogenous agonists of these receptors and their origin remain unknown.
Summary This review addresses the questions whether independent angiotensin generation truly occurs in the brain, what its
relationship with the kidney is, and how centrally acting RAS blockers/agonists might work.
Keywords Brain renin-angiotensin system .AminopeptidaseA inhibitor .AT2 receptor .Angiotensinogen .Kidney .Sympathetic
nervous system . Stroke
Introduction
Angiotensinogen is the precursor of all angiotensin (Ang)
metabolites. Although its major source is the liver, addi-
tional sites of angiotensinogen synthesis have been report-
ed, the most important of which are the brain, kidney, and
adipose tissue [1•, 2–7]. Renin, in contrast, is derived
from one source, the kidney. Its precursor, prorenin, like
angiotensinogen, remarkably has several sources, includ-
ing the kidney, ovaries, testis, and adrenal [8]. Yet, given
the fact that prorenin is inactive, it would require a (lo-
cal?) activation mechanism to be of importance. Here, the
(pro)renin receptor, which binds and activates prorenin
in vitro, has been proposed as a major player [9].
Unfortunately however, its affinity for prorenin is too
low to allow this phenomenon to play any role in vivo
[10], and the concept of (pro)renin receptor-prorenin in-
teraction as a unit allowing local Ang I-generating activity
is now being abandoned [11]. This does not mean that the
(pro)renin receptor has no role at all—in contrast, given
its ubiquitous abundance, its link with vacuolar H+-
ATPase, and the lethal consequences of its deletion, it
turns out to be of vital importance [12–15], yet apparently
independently of the renin-angiotensin system (RAS).
Taken together, the various sites of renin, prorenin, and
angiotensinogen synthesis allow multiple possibilities for
angiotensin generation, e.g., in circulating blood from re-
nal renin and hepatic angiotensinogen, or at tissue sites,
from either locally synthesized angiotensinogen and
prorenin, or renin, prorenin, and angiotensinogen taken
up from blood. Yet, regarding prorenin, we still lack a
detailed insight into how it might display activity. This
review focuses on the brain RAS, critically addressing
the questions whether independent angiotensin generation
occurs in the brain, what its relationship with the kidney
is, and how centrally acting RAS blockers (in particular,
the recently introduced aminopeptidase A inhibitors) and
activators (Ang II type 2 (AT2) and Mas receptor agonists)
might work.
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Independent Angiotensin Generation
in the Brain?
Given the presence of the blood-brain barrier, diffusion of
circulating renin, prorenin, or angiotensinogen into the brain
is impossible (Fig. 1). Although early studies were able to
demonstrate renin-like activity in the brain [16], its origin
remained uncertain. Here, one has to consider that brain tissue,
when homogenized, of course contains minute amounts of
trapped blood, and thus brain renin measurements have to be
corrected for such admixture. Recently, making use of differ-
ent mouse brain nuclei, we performed such correction, and in
parallel experiments perfused the brain with buffer to remove
as much blood as possible prior to brain tissue homogeniza-
tion [1•]. Data revealed that, although renin was easily detect-
able in brain nuclei, it could be entirely explained based on the
presence of trapped blood in brain tissue—indeed, it disap-
peared after buffer perfusion. Moreover, we found no evi-
dence for the synthesis of prorenin in the brain, not even under
circumstances where activation of the brain RAS has been
proposed, i.e., the deoxycorticosterone acetate (DOCA)-salt
model [17, 18]. Around the same time, it was concluded that
“intracellular renin,” a renin isoform derived from an alterna-
tive transcript of the renin gene, lacking the signal peptide and
part of the prosegment (and hence being unable to leave the
cell) also does not contribute to brain angiotensin generation
[19]. In fact, if anything, it suppressed brain RAS activity,
although the underlying mechanism remains unknown.
Taken together, these data, in combination with the exception-
ally low (and often impossible to detect at all) renin mRNA
expression of the brain [1•, 20], rule out a role for renin or
prorenin in local angiotensin generation at brain tissue sites.
Data on the presence of angiotensinogen in the brain are
more convincing. Multiple studies report detectable brain
angiotensinogen levels that do not run in parallel with circu-
lating angiotensinogen levels [4, 6]. Yet, generally, brain
angiotensinogen levels still at most correspond with a few
percent of plasma angiotensinogen levels, in a wide range of
species, and thus admixture from blood cannot be entirely
ruled out. Importantly, brain angiotensinogen mRNA levels,
albeit being several orders of magnitude below those in the
liver, are not as excessively low as those of renin [1•]. At this
stage, the ultimate proof for local synthesis (showing the pres-
ence of angiotensinogen in the brain of animals lacking hepat-
ic angiotensinogen expression) is still awaited. When apply-
ing this approach to other organs claimed to synthesize
angiotensinogen (kidney and adipose tissue) it turned out that
their angiotensin generation depended entirely on hepatic
angiotensinogen, implying that local angiotensinogen synthe-
sis in these organs, if occurring at all, has no functional con-
sequence [2, 3, 7]. If angiotensinogen synthesis truly occurs in
the brain, a complicating factor remains the absence of renin.
This would require non-renin enzymes to cleave
angiotensinogen. There is currently no in vivo evidence for
this concept.
Angiotensins have been reported in brain tissue in widely
varying levels. In some cases, levels (expressed per gram tis-
sue) were even higher than those in the kidney [17, 18]. This is
hard to believe given the low angiotensinogen levels, and the
absence of renin in the brain. Issues that need to be considered
here are the use of very small tissue pieces for angiotensin
measurements (often representing selected brain nuclei), the
detection limit problems that arise from this approach (inher-
ent to brain research), and the absence of rigorous separation
Fig. 1 Current understanding of the origin of brain renin-angiotensin
system (RAS) components. Circulating renin, prorenin, and
angiotensinogen (Agt) are unlikely to pass the blood-brain barrier
(BBB). Intracellular (i.c.) renin does not contribute to brain RAS
activity. Agt has been shown in brain cells and cerebrospinal fluid, yet
whether actual release from cells into cerebrospinal fluid occurs remains
unclear, nor do we know how brain cell-derived Agt contributes to local
angiotensin (Ang) generation in the absence of renin. Circulating Ang II
may bind to brain Ang II type 1 or 2 (AT1, AT2) receptors (R) outside the
BBB, or could diffuse into the brain under conditions where the BBB is
disturbed (right part of the figure), like in hypertension. Possibly, such
diffusion results in local formation of Ang-(1-7) and subsequent Mas
receptor stimulation
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techniques to distinguish true angiotensin from background
noise. As an example, measuring an angiotensin (Ang) II level
at the detection limit of the assay (often around 2 fmol/sample)
in 10 mg brain tissue results in a theoretical tissue level of
200 fmol/g. At the same time, measuring 50 fmol Ang II in
0.5 g renal tissue (i.e., well above the detection limit), would
translate to 100 fmol/g. On this basis, it seems that brain Ang
II levels are higher in the brain than in the kidney, although in
reality, they may be zero.
When employing liquid chromatography-tandem mass
spectrometry (LC-MS/MS) to quantify the individual angio-
tensin metabolites, a highly sensitive method with little or no
background noise, we were unable to detect Ang I in brain
tissue of spontaneously hypertensive rats (SHR) [1•]. Brain
Ang II occurred at levels that were ≈ 25% of the levels in
plasma, i.e., they were several orders of magnitude below
those in the kidney [21, 22]. Since Ang II type 1 (AT1) recep-
tor blockade reduced the brain/plasma Ang II ratio by > 80%,
and in view of the absence of Ang I, the most likely origin of
brain Ang II is accumulation of circulating Ang II via binding
to AT1 receptors (explained further later) [21, 23].
Additionally, considering its much smaller size versus renin
and angiotensinogen, Ang II may gain access to the brain
under conditions where the blood-brain barrier is (partially)
disrupted, e.g., in hypertension. In fact, Ang II itself is capable
of disrupting this barrier [24, 25]. Once in the brain, Ang II
might be converted to metabolites, like Ang III and Ang-(1-7).
However, at least in SHR, we were unable to demonstrate
these metabolites [1•], and thus whether angiotensin metabo-
lites other than Ang II truly reach meaningful levels in the
brain is still uncertain.
The “Reno-Cerebral Reflex”
Salt intake promotes progression of chronic kidney disease.
Cao et al. have suggested that renal inflammation, as occur-
ring in the 5/6 nephrectomy rat model following exposure to
high salt, results in oxidative stress and subsequent activation
of the sympathetic nervous system [26•]. Under these condi-
tions, AT1 receptors and Ang II (determined semiquantitative-
ly by double-staining immunofluorescence), tyrosine hydrox-
ylase (the rate-limiting enzyme for norepinephrine synthesis),
and oxidative stress markers (Nox2 and Nox4) were upregu-
lated in the brain. Remarkably, intracerebroventricular appli-
cation of losartan or tempol (a reactive oxygen species scav-
enger) prevented this, as did renal denervation. Moreover,
these procedures also prevented the paradoxical upregulation
of the renal RAS (reflected by elevated angiotensinogen, ACE
and AT1 receptor levels) following high salt in this rat model.
This eventually led to reduced renal inflammation and fibro-
sis. Based on these findings, the authors proposed that a there
is a “reno-cerebral reflex” resulting in a positive feedback
mode, further worsening kidney function (Fig. 2). Similar ob-
servations were made in a mouse renal ischemia-reperfusion
model under normal salt conditions [27]. Importantly, in both
models, the renal RAS upregulation occurred independently
of renin, since renin was either unchanged (mouse ischemia-
reperfusion model) or severely downregulated (rat 5/6 ne-
phrectomy model during high salt). This is highly unusual,
since it is normally renin that allows the up- or downregulation
of angiotensin levels [28, 29]. The authors attributed this renal
RAS upregulation to the increased renal angiotensinogen ex-
pression. Yet, it has already been shown that renal
angiotensinogen does not contribute to renal angiotensin gen-
eration, neither under normal nor pathological conditions [2,
3]. Furthermore, as an indication of the brain RAS, Cao et al.
identified angiotensinogen- and Ang II-positive cells in the
brain, making use of anti-angiotensinogen and anti-Ang II
antibodies. Given the exceptional low Ang II levels in the
brain, Ang II “quantification” by double-staining immunoflu-
orescence should be interpreted with the utmost care, particu-
larly given the inconsistencies obtained with antibodies
against RAS components [30]. Why angiotensinogen, a pro-
tein which is normally secreted and not stored intracellularly,
was observed in brain cells remained unexplained, nor did the
authors investigate brain renin. Taken together, although of
course the sympathetic connection between brain and kidney
is well established (and known to play a vital role in blood
pressure regulation and the pathogenesis of hypertension),
whether sympathetic activation truly results in significant an-
giotensin generation at brain tissue sites cannot be concluded
from these data. An alternative explanation might be that
systemic Ang II, particularly in combination with high salt,
via binding to brain AT1 receptors outside the blood-brain
barrier (e.g., in the subfornical organ or the organum
vasculosum laminae terminalis) results in the activation of
angiotensinergic projections into brain nuclei within the
blood-brain barrier (like the paraventricular nucleus and the
rostroventrolateral medulla) [31]. Indeed in rats, subcutane-
ous infusion of low-dose Ang II alone marginally affected
blood pressure, while in combination with high salt, it mas-
sively increased blood pressure and upregulated aldosterone
[32•]. Central application of either losartan or amineralocor-
ticoid receptor blocker prevented this. Clearly, these latter
data show that protective effects of intracerebroventricular
application of an AT1 receptor blocker can also be due to
interference with systemic Ang II acting in the brain.
Similarly, the protective effect of centrally applied mineral-
ocorticoid receptor blockers might relate to blockade of ef-
fects of circulating aldosterone in brain nuclei outside the
blood-brain barrier, particularly because brain and plasma
aldosterone levels were found to correlate closely. In conclu-
sion, before concluding that elevated brain Ang II “positivi-
ty” truly reflects activation of the brain RAS based on a reno-
cerebral reflex, we need to determine that this is not due to
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uptake of circulating Ang II into nuclei outside the blood-
brain barrier, nor to the disruptionof this barrier (as occurring
during pathological conditions, including a high-salt diet)
causing uptake by nuclei within the blood-brain barrier, like
the brain stem and hypothalamus [25, 33]. Here, it is impor-
tant to realize, as stated above, that Ang II itself is capable of
disrupting this barrier. Moreover, central application of an
AT1 receptor antagonist prevented the central effects of sys-
temic Ang II, and thus effects of centrally applied drugs can-
not be taken as evidence for selective interferencewith brain-
derived Ang II. Finally, the sympathetic nervous system is a
well-known stimulator of renin release, and thus elevating
renal sympathetic nervous activity is likely to activate the
renal RAS, yet not necessarily via brain RAS activation.
Central Aminopeptidase A Inhibition
Apart from Ang II, its metabolite Ang III, generated by ami-
nopeptidase A (APA), is an alternative activator of AT recep-
tors. It displays similar affinity for the AT1 receptor, and might
even be the preferred agonist of the AT2 receptor. Assuming
that the latter receptor exerts beneficial effects, e.g., coronary
vasodilation and diuresis [34–36], blocking APA seems coun-
terintuitive in hypertension. Yet, it has been claimed that in the
brain Ang III rather than Ang II is the endogenous AT1 recep-
tor agonist, and on the basis of this concept centrally acting
APA inhibitors are now being tested in hypertensive patients.
This claim relates to the observation that central application of
Ang II did not affect vasopressin release (a well-known effect
of central AT1 receptor activation) when simultaneously
blocking APA with EC33, while simultaneous inhibition of
aminopeptidase N (APN, the enzyme that degrades Ang III)
with PC18 enhanced the effects of Ang II on vasopressin
release [37]. Since the Ang II effects were blocked by an
AT1 receptor antagonist, it was concluded that they involved
AT1 receptor stimulation by Ang III rather than by Ang II.
However, the authors did not quantify brain Ang III in vivo
during these procedures, and thus the underlying biochemical
evidence for this concept is still lacking. Confusingly, when
employing LC-MS/MS we were unable to demonstrate Ang
III in the brain [1•], while others observed identical responses
to Ang II and Ang III following intracerebroventricular appli-
cation, even when making use of APA-resistant analogues
[38]. An alternative explanation of the findings on APA and
APN inhibition during Ang II application should therefore be
considered, i.e., the possibility that such inhibition interferes
with pathways beyond the RAS. This is not unlikely since
these aminopeptidases not only act on multiple substrates,
but are also ubiquitously present in- and outside the brain.
Nevertheless, an EC33 prodrug, RB150, has now been syn-
thesized which is capable of passing the blood-brain barrier.
This drug decreased blood pressure in DOCA-salt rats [39•],
but also attenuated cardiac dysfunction after myocardial in-
farction [40]. As expected, it reduced vasopressin and in-
creased diuresis. A Phase IIa study assessed the blood
pressure-lowering effect of a 4-week oral application of
RB150 (also known as QGC001 or firibastat) in 34 patients
with grade I or II essential hypertension (EudraCT number
2014-003071-37, unpublished results). Although there were
no significant effects on blood pressure versus placebo, the
drug was found to be safe and did not affect renin. At the
recent American Heart Association meeting in Chicago
(November 2018), a follow-up trial (NEW-HOPE,
NCT03198793, unpublished results) in a much larger hyper-
tensive, overweight subject population of multiple ethnic ori-
gin (n = 250) reported antihypertensive effects of the drug
(250 mg, 500 mg, or 500 mg + 25 mg hydrochlorothiazide)
over an 8-week treatment period. A detailed analysis of its
dose-dependency and the effect of adding hydrochlorothia-
zide was not provided, and the trial did not include a placebo
arm. Taken together, APA inhibition may well be a promising
Fig. 2 The reno-cerebral reflex. Renal inflammation, fibrosis, and
oxidative stress, as occurring in chronic kidney disease models like the
5/6 nephrectomy (Nx) model (in the presence of a high-salt diet) or after
renal ischemia + reperfusion, result in sympathetic nervous system
activation, which via activation of the brain renin-angiotensin system
(RAS) is believed to subsequently upregulate renal angiotensinogen,
thereby inducing renal RAS stimulation. A simpler explanation might
be that sympathetic activation directly upregulates renal renin synthesis,
since this is a well-known consequence of β-adrenergic receptor
stimulation, not requiring brain RAS activation
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novel treatment strategy in patients displaying low systemic
RAS activity (like in DOCA-salt-treated rats) but whether this
truly involves suppression of brain Ang III remains to be
proven (Fig. 3).
AT2 and Mas Receptor Agonism in the Brain
AT1 receptor blockers have often been suggested to offer ce-
rebrovascular protection, in contrast to ACE inhibitors, al-
though clinical evidence for this concept is still missing [41].
The underlying mechanism of this concept would be that only
AT1 receptor blockers allow central AT2 receptor agonism.
Possibly, AT2 receptor stimulation by endogenous Ang II
might already exert protective effects. Indeed, the neurological
deficit after middle cerebral artery occlusion was greater in
AT2 receptor knockout mice, and without AT2 receptors, the
beneficial effects of AT1 receptor blockade were diminished
[42]. Now that AT2 receptor agonists like C21 are available,
the next step is to evaluate these drugs in stroke models, like
the middle cerebral artery occlusionmodel and the endothelin-
1-induced ischemic stroke model. Indeed, in both models,
C21 exerted cerebroprotection, not only when applied
intracerebroventricularly, but also when applied systemically
[43, 44]. To explain the efficacy of the latter approach, con-
sidering that C21 cannot pass the blood-brain barrier, it has to
be assumed that C21 enters the brain under conditions where
this barrier has been disturbed, like in the above models. An
exciting novel approach is to administer C21 via the nose-to-
brain route to bypass the blood-brain barrier [45•]. When ap-
plying C21 via this route at 1.5 h after stroke, it reduced infarct
size and improved neurological scores. Furthermore, angio-
tensin-(1-7) (Ang-(1-7)), generated from Ang II by ACE2,
also offers neuroprotection, both when applied centrally and
orally, as did the putative ACE2 activator diminazene [46].
Ang-(1-7) is believed to act via Mas receptors. One possible
explanation for the identical beneficial effects of AT2 and Mas
receptor stimulation is that both receptors co-localize and are
functionally interdependent [47]. Importantly, none of these
approaches supports actual angiotensin synthesis in the brain
allowing AT2/Mas receptor activation by endogenous angio-
tensins. A further complicating factor is that both C21 and
diminazene exert AT2 receptor- and ACE2-independent ef-
fects, respectively [48, 49], while Ang-(1-7) was recently re-
ported not to act as Mas agonist at all [50]. Clearly, these
observations remain controversial, and even if they can be
taken as evidence for AT2/Mas receptor activation, they do
not automatically imply that these receptors are normally seen
by brain-derived endogenous agonists. In fact, their stimula-
tion may depend on breakdown of the blood-brain barrier
(Fig. 1), allowing circulating angiotensins access to brain re-
ceptors [42].
Conclusion
Convincing evidence that angiotensin synthesis occurs inde-
pendently at brain tissue sites is lacking. Renin is absent and
brain angiotensin levels are exceptionally low as compared to
other organs. In fact, they may well represent binding of cir-
culating Ang II to brain AT1 receptors in brain nuclei outside
the blood-brain barrier. To investigate whether brain-
originating angiotensinogen, if existing, contributes to brain
angiotensin synthesis, experiments need to be performed un-
der conditions where hepatic angiotensinogen synthesis is si-
lenced, preferably in a model where brain angiotensin is as-
sumed to play an important role, like the DOCA-salt rat.
Before concluding that novel therapies aimed at APA, APN,
ACE2, AT2, and Mas receptors interfere with the brain RAS,
we not only need to exclude non-specific effects of the applied
drugs, but also show that they truly affect brain angiotensin
levels, and that this explains their effects. In other words, it
would help to demonstrate brain-selective Ang III suppression
during RB150 treatment, and Ang-(1–7) upregulation after
Fig. 3 Formation of angiotensin (Ang) III and Ang-(1-7) from Ang II,
and the receptors which are believed to be activated by the various
angiotensin metabolites. The application of central aminopeptidase A
(APA) inhibitors is based on the concept that Ang III is the endogenous
activator of AT1 receptors, resulting in vasopressin release.
Aminopeptidase N (APN) degrades Ang III to the inactive Ang IV. Yet,
others argue that Ang II is the preferred agonist of this receptor, while
both agonists may also bind to AT2 receptors. The latter heterodimerize
with Mas receptors, potentially explaining the identical neuroprotective
effects observed with AT2 and Mas receptor agonists in stroke models
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diminazene. Here, the application of a highly sensitive method
with little or no background noise like LC-MS/MS is essen-
tial. Yet, given the fact that APA, APN, and ACE2 have mul-
tiple other substrates, one simultaneously needs to rule out that
effects are seen due to interference with these alternative
substrates.
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